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Abstract 
Background: Acute kidney injury (AKI) is a common complication after 
coronary artery bypass grafting (CABG) surgery, and is associated with major 
adverse outcomes. The effect of preoperative administration of coenzyme Q10 
was evaluated to realize that whether it could prevent the occurrence of AKI 
following elective CABG surgery.  
Materials and Methods: Two hundred and fifty patients who were a 
candidate for elective CABG surgery between September 2017 and August 
2018 were randomly assigned to intervention group (receiving coenzyme Q10, 
300 mg BID for 2 days before surgery) and control group. Serum NGAL 
(neutrophil gelatinase-associated lipocalin) was measured at baseline, 6, and 
24 hours after surgery. Serum creatinine (sCr) and urine output (UO) were 
also measured at baseline and after surgery.  
Results: Fifty patients completed the study. The total incidence of acute 
kidney injury was 32%. There were no significant differences in the 
incidence of AKI (p=0.07) between the two groups. Serum NGAL was 
shown no significant difference at 6 (p=0.13) and 24 (p=0.22) hours after 
surgery compared to the baseline level between the two groups, whereas, the 
significant difference in the hospitalization duration was shown between 
them (p=0.02).  
Conclusion: CoQ10 supplementation did not significantly decrease the 
incidence of AKI in patients undergoing elective CABG.  
Keywords: Ubiquinone, Coenzyme Q10, Acute kidney injury, Coronary artery 
bypass grafting surgery, Neutrophil gelatinase-associated lipocalin protein 
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Acute kidney injury is a complication, which occurs 
frequently in post-cardiac surgery cases and can be 
linked to increased morbidity and mortality (1). It is 
also true that cardiac surgery is the second most 
common cause of AKI in intensive care units (ICU) 
(2). Overall mortality after open-heart surgery could 
be as high as 8% and among patients who develop 
severe AKI who are in need to dialysis, it can reach 
up to 88% (3). 
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Pharmacological interventions may be 
considered to reduce the occurrence of renal injury in 
patients without evidence of acute renal dysfunction 
as primary prevention (4). There is a growing body of 
evidence suggesting a detrimental role of free oxygen 
radical species in the development of AKI (5). The 
beneficial role of endogenous and synthetic 
antioxidants in the prevention of AKI has been 
demonstrated in animal and cell-based models (6). 
However, the data regarding the renal 
protective effect of synthetic antioxidant 
supplementation in human AKI and renal diseases are 
more ambiguous (7). Coenzyme Q10 (CoQ10) may 
have the potential for preventing and treating 
cardiovascular disease, improving cardiac function, 
and decreasing oxidative stress in patients with renal 
impairment (8). CoQ10 supplementation improves 
glycemic control and vascular dysfunction in type II 
diabetes, enhances renal function in patients with 
chronic kidney disease, and reduces inflammation. 
The beneficial role of supplemental CoQ10 may be 
considered as a result of cellular energy generation, 
antioxidant, and anti-inflammatory properties (9). 
Coenzyme Q10 (CoQ10) has been used as an 
antioxidant to prevent AKI in patients (10). However, 
no published study has systematically and 
comprehensively summarized the renoprotective 
effect of CoQ10 after CABG. This study aimed to 
examine the prophylactic effect of CoQ10 on acute 
kidney injury in post-CABG patients. 
Methods 
After receiving approval from the University Ethics 
Committee and obtaining written informed consent 
(ethics code: IR.SBMU.PHNM.1394.311), fifty adult 
patients who underwent elective CABG at a teaching 
hospital were recruited for this randomized control 
trial. Exclusion criteria for the study were as follows: 
patients who needed emergency CABG, high-risk 
patients such as those who needed concurrent valvular 
surgery and CABG, presence of known drug allergy 
to CoQ10, history of chronic kidney disease (stage IV 
and V), preoperative creatinine clearance less than 30 
ml/min and history of chronic hepatic disease (liver 
function test three times the upper limit). 
Using a computer-based randomization 
method, the patients in the intervention group 
received CoQ10, 300 mg tablet, twice a day, for 2 
days before the surgery (n=25). Patients in the control 
group did not receive CoQ10. The same routine 
treatment regimen was administered in both groups.  
Patients underwent standard intravenous 
anesthesia as follows: All patients were premedicated 
with lorazepam of 2 mg orally and morphine of 0.15 
mg/kg intramuscularly 2h and 30 min before surgery 
respectively. Anesthesia was induced by fentanyl of 5 
mcg/kg, thiopental of 3 mg/kg and atracurium of 0.5 
mg/kg and was maintained with fentanyl 1–2 
mcg/kg/h, propofol 50-70 mcg/kg/min and atracurium 
10 mcg/kg/h. All patients received heparin 300-400 
IU/kg before CPB (Cardiopulmonary bypass) to 
achieve an activated clotting time (11) of more than 
480 sec. Surgery was done according to standard on-
pump and mild hypothermia. During CPB, to achieve 
the target ACT, additional heparin was prescribed, 
and after the separation from CPB and heparin 
neutralization, protamine sulfate (1 mg per 100 units 
of heparin) was given to reach the targeted ACT level 
(80–120 sec). 
Patients have received epinephrine infusion 
after CPB when SBP was less than 90mmHg and they 
were paced regarding keep HR more than 70/min. All 
patients were transferred to the intensive care unit 
(ICU) and received mechanical ventilation with 
synchronized intermittent mandatory ventilation 
(SIMV) and pressure support (PS) mode after surgery 
and in the ICU. They were weaned and extubated 
during the first hours after arrival according to the 
standard weaning protocol.  
During preoperative hospitalization, laboratory 
values such as complete blood count (CBC), sodium, 
potassium, magnesium, calcium, phosphorus, 
albumin, urea, serum creatinine, and blood sugar were 
measured daily. Postoperative arterial blood gases 
(ABG) and lactate were measured within the first 24 
hours if required, while urine output was measured 
hourly during ICU stay. Patients were transferred to 
the cardiac care unit (CCU) on day 2 after surgery 
based on the following criteria: being 
hemodynamically stable with acceptable oxygenation 
and ventilation, being conscious, having no life-
threatening arrhythmias, active bleeding, electrolyte 
abnormality, delirium, and severe anemia (Hgb <8 
g/dL). A urinary catheter and pericardial drain were 
removed before patients were transferred to CCU. 
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AKI based on acute kidney injury network (AKIN) 
classification was defined as abrupt (within 48 h) 
increase in serum creatinine of 0.3 mg/dL or more 
(≥26.4 μmol/L) or a percentage increase in serum 
creatinine of 50% or more (1.5-fold from baseline) or 
reduction in urine output (documented oliguria of < 
0.5 mL/kg/h for >6 h) (12). Recovery from AKI was 
defined as the return of serum creatinine or 
glomerular filtration rate to the baseline value. 
Neutrophil Gelatinase-associated Lipocalin was used 
to evaluate renal function. Serum NGAL was 
measured by enzyme-linked immunosorbent assay 
(13) at baseline and 6 and 24 hours following surgery. 
Serum creatinine (sCr) was measured at baseline and 
then 24, 48, and 72 hours post operatively. As a 
secondary outcome, C reactive protein (CRP) was 
measured by hs-CRP before and 24 hours after 
CABG. 
The categorical variables were presented as 
percentage and continuous variables were compared 
using the Student's t-test for normally distributed 
values and the Mann–Whitney U test for non-
normally distributed variables. Proportions were 
compared using the Chi-square test. Statistical 
analysis was performed using SPSS® version 24 
(IBM SPSS, Chicago, IL, USA). Statistical 
significance was considered as p<0.05. 
 
Figure 1. CONSORT flow diagram. 
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Results 
Fifty patients with a mean age of 59.3±9.88 (ranging 
from 50 to 70) years completed the study. Of these 
patients, 37 were males and 13 were females. One 
patient died in the control group (Figure 1). 
Differences between the two groups in terms of 
demographic data (age, sex, BMI) comorbidities 
(diabetes, hypertension), cardiovascular status, and 
the number of grafts were not statistically significant 
(Table 1). Moreover, there were no significant 
differences among patients' duration of surgery, 
duration of ischemia, and pump time (Table 2). 
Based on AKIN criteria, AKI was seen in 32% 
of patients with no clinically significant difference in 
incidence, severity, and duration of AKI between the 
two groups. The incidence of CABG associated AKI 
was 20% and 44% in CoQ10 and control groups, 
respectively (p=0.07). The NGAL baseline levels 
were not statistically significant between the two 
groups (94.92±81.46 in the CoQ10 group versus 
125.37±117.07 in the control group, p=0.8). 
Fluctuation in serum creatinine levels between 
the two groups was evaluated at 24, 48, and 72 hours 
postoperatively. Results demonstrated a larger change 
in postoperative sCr levels for the control group but 
were not clinically significant (Table 3). 
Measurements of NGAL at 6 and 24 hours 
after CABG showed no clinically significant changes 
between the two groups (-64.76±45.53 in CoQ10 
group versus -113.33±46.37 in the control group, 
p=0.13; -54.96±51.67 in CoQ10 group versus -
109±117.53 in the control group, p=0.22, 
respectively). Moreover, assessment of sCr, U/O, and 
CRP levels after surgery revealed no statistically 
significant differences between the two groups (Table 
3).  
As shown in table 4, There were no significant 
differences in the duration of mechanical ventilation 
(p=0.1) and the ICU length of stay (p=0.99) between 
the two groups. Duration of hospitalization was 
considerably shorter in the CoQ10 group (p=0.02). 
Data regarding CVP, BP, Hgb, Hct, BUN, and Alb 
are provided as well in Table 4. 
Discussion 
Fluid balance optimization, establishing adequate 
perfusion, and avoidance of nephrotoxic drugs 
(Diuretics, ACE inhibitor/ARBs, NSAIDs) are 
amongst strategies that can be used to avoid renal 
complications (14). Several drugs, including N-acetyl 
cysteine, have been used to prevent AKI after cardiac 
surgery; however studies failed to demonstrate their 
effectiveness (15). Many studies have evaluated the 
effect of novel renoprotective drugs, namely 
Table 1: Demographic data and clinical characteristics. 





Age (year) 64.92±8.70 60.88±9.76 0.11 
Sex (male) 16(64%) 21(84%) 0.11 
BMI (kg/m2 ) 25.76±3.35 26.45±3.79 0.69 
BSA (m2) 1.76±0.15 1.78±0.21 0.5 
Diabetes 10(40%) 6(24%) 0.23 
Hypertension 8(32%) 6(24%) 0.53 
EF(%) 44.60±7.89 43.96±8.48 0.83 
3VD 17(68%) 18(72%) 0.76 
BMI: Body Mass Index, BSA; Body Surface Area, EF: Ejection Fraction, 3VD: Three-vessel disease  
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dopamine, fenoldopam, calcium channel antagonists, 
natriuretic peptides, and diuretics, although the results 
of these studies might not be much reliable because of 
the poor quality of these studies (16). Moreover, to 
inspect the beneficial role of antioxidants in the 
prevention of AKI following cardiac surgery, several 
studies investigated the impact of preoperative 
administration of antioxidants such as selenium and 
vitamin C. These studies revealed that preoperative 
administration of vitamin C and selenium was not 
effective in preventing AKI and associated morbidity 
and mortality after coronary artery bypass graft 
surgery (17, 18). Our study revealed that CoQ10 as a 
preventive measure seems to have no effects on the 
occurrence of AKI in patients following CABG. The 
results regarding postoperative AKI incidence and 
NGAL measurements showed no significant 
differences between CoQ10 and the control group. 
Table 2: Surgical factors data. 





Operation time (minutes) 236.8±34.09 263.32±61.43 0.06 
Pump time (minutes) 72.36±17.29 85.36±30.19 0.07 
Ischemic time (minutes) 44.28±12.25 56.16±30.73 0.23 
 
Table 3: Assessment of renal function in patients. 





Baseline NGAL (ng/ml) 94.92±81.46 125.37±117.07 0.8 
NGAL changes 0-6 h -64.76±45.53 -113.33±46.37 0.13 
NGAL changes 0-24 h -54.96±51.67 -109±117.53 0.22 
Baseline sCr (mg/dl) 1.07±0.26 1.24±0.23 0.02 
sCr changes 0-24 h -0.078±0.26 -0.20±0.38 0.21 
sCr changes 0-48 h -0.05±0.17 -0.17±024 0.07 
sCr changes 0-72 h -0.07±0.18 -0.15±0.23 0.14 
U/O changes 0-6 h 688.04±473.12 545±751.82 0.48 
U/O changes 0-12 h 1725.4±852.97 1505±1010.75 0.41 
U/O changes 0-24 h 2970±931.07 2997±1400.78 0.6 
Baseline CRP (mg/l) 16.06±12.33 14.86±14.12 0.41 
CRP changes 0-24 h -39.61±15.94 -41.08±12.86 0.32 
NGAL; neutrophil gelatinase-associated lipocalin, CRP: C-Reactive Protein, sCr: Serum creatinine, U/O: Urine Output 
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AKI is characterized by abrupt deterioration in kidney 
function, the diagnosis of which depends on serum 
creatinine measurements. Early detection and timely 
treatment are the keys to the successful treatment of 
AKI (19). Unfortunately, creatinine is a delayed and 
unreliable indicator of AKI (20). Nevertheless, 
understanding the early stress response of the kidneys 
to acute injuries has revealed several potentially 
useful biomarkers (21). The discovery, translation, 
and validation of NGAL, a sensitive and specific 
early marker of AKI, arguably is the most promising 
novel AKI biomarker that has been examined and 
analyzed (22, 23). NGAL is emerging as an excellent 
standalone troponin-like biomarker in the plasma and 
urine with the aim of AKI prediction, clinical trials 
monitoring in AKI cases and the prognosis of AKI in 
several common clinical scenarios (24). The 
protective effect of CoQ10 for AKI has been 
Table 4: Secondary outcomes analysis. 







4.84±0.89 4.12±2.12 0.10 
Baseline CVP (mmHg) 10.12±2.50 10.56±4.86 0.64 
CVP before CABG (mmHg) 12.75±3.26 11.47±3.64 0.22 
CVP 6h after CABG (mmHg) 14.04±3.04 11.88±3.91 0.04 
CVP 24h after CABG (mmHg) 14.08±3.17 13.48±3.58 0.31 
Hospitalization Duration (day) 8.32±1.79 10.6±3.69 0.02 
Length of Stay in ICU (day) 4.72±1.42 4.68±1.28 0.99 
BP systolic baseline (mmHg) 110.83±8.23 118.17±13.98 0.06 
BP systolic change 0-24 3.5±9.71 -15.62±33.85 0.02 
BP Diastolic baseline (mmHg) 71.55±13.84 80.77±11.39 0.04 
BP Diastolic change 0-24 0.87±8.5 -11.08±17.80 0.03 
Hgb baseline (g/dl) 13.80±2.05 14.27±1.47 0.37 
Hgb change 0-24 -2.64±2.17 -3.34±1.48 0.19 
Hct baseline (%) 40.16±5.15 41.78±3.87 0.21 
Hct change 0-24 -7.74±4.37 -9.39±4.46 0.19 
BUN baseline (mg/dl) 34.24±10.17 36.48±13.27 0.81 
BUN change 0-24 1.85±11.66 -4.29±12.10 0.08 
Alb baseline (g/dl) 3.76±0.83 3.72±0.67 0.87 
Alb change 0-24 -0.39±1.54 -0.41±0.76 0.96 
CVP: Central Venous Pressure, ICU: Intensive Care Unit, BP: Blood Pressure. Hgb: Hemoglobin 
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proposed for its antioxidant effects (25, 26). Large 
population-based studies have supported that CoQ10 
supplementation attenuates gentamicin-induced renal 
injury via decreasing necrotic tubule rate and hyaline 
accumulation in tubule (27). Takenaka et al proposed 
that coenzyme Q10 could have protective effects on 
AKI in warm ischemic injuries of the animal 
models(28). Likewise, Akira Ishikawa suggested the 
therapeutic effects of Ubiquinol, which may be a 
candidate for the treatment of patients with kidney 
disease (29). However, their findings were 
inconclusive. Unfortunately, these previous findings 
were not confirmed by our study. To our knowledge, 
this is the only study exploring the protective effect of 
CoQ10 in the prevention of AKI following cardiac 
surgery in humans. Our results are consistent with 
other reports that suggested CoQ10 was not effective 
in reducing renal damage (30, 31). In contrast, an 
original article demonstrated the protective effect of 
CoQ10 against free radical oxidative damage which 
can harm kidney function after CABG (32). A 
systematic review and meta-analysis was performed 
to elucidate the role of CoQ10. Favorable effect of 
CoQ10 was revealed when considered as a 
prophylactic treatment for preventing complications 
in patients undergoing cardiac surgery with 
cardiopulmonary bypass. However, high-quality 
randomized controlled trials are required to clarify 
this role (10). The administration of CoQ10 in the 
prevention of contrast-induced nephropathy (CIN) 
after coronary angiography has been associated with 
different results (33). None of the patients in this 
study required renal replacement therapy during 
hospitalization. This study had a few limitations as 
well. Firstly, because of the high cost and resource 
limitations of parenteral CoQ10 in our institution, we 
used oral forms of the medication, which has a 
different bioavailability compared to its parenteral 
form. Furthermore, the small sample size might have 
precluded our results from being significant. 
Therefore, our results cannot be extrapolated to high-
risk patients or those undergoing emergency CABG. 
We would recommend further studies with larger 
sample size. 
As patients with a history of chronic kidney 
disease and valvular heart disease, the two main risk 
factors contributing to AKI incidence, were excluded 
from the study (34); the results obtained in this study 
could not be extrapolated to this population. 
Occasionally asymptomatic acute kidney injury 
may happen in patients after their discharge from the 
hospital (35). Considering the follow-up duration in 
this study that was during the patient’s hospital stay, 
some cases may have been missed in our research. 
Finally, further studies with different doses and 
administration duration of CoQ10 as well as 
analyzing other AKI biomarkers such as IL-18, KIM-
1, L-FABP, and Cystatin-C are recommended. 
Conclusion 
In conclusion, we found that the preoperative 
administration of CoQ10 could not reduce the 
incidence of AKI and its associated morbidity and 
mortality in patients undergoing CABG. Further high-
quality RCTs are needed to clarify the potential 
prophylactic effect of CoQ10 on surgery-related AKI. 
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